Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas
- PMID: 38631437
- DOI: 10.1016/j.mrrev.2024.108492
Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas
Abstract
A pathology-supported genetic testing (PSGT) framework was established in South Africa to improve access to precision medicine for patients with breast carcinomas. Nevertheless, the frequent identification of variants of uncertain significance (VUSs) with the use of genome-scale next-generation sequencing has created a bottleneck in the return of results to patients. This review highlights the importance of incorporating functional genomics into the PSGT framework as a proposed initiative. Here, we explore various model systems and experimental methods available for conducting functional studies in South Africa to enhance both variant classification and clinical interpretation. We emphasize the distinct advantages of using in vitro, in vivo, and translational ex vivo models to improve the effectiveness of precision oncology. Moreover, we highlight the relevance of methodologies such as protein modelling and structural bioinformatics, multi-omics, metabolic activity assays, flow cytometry, cell migration and invasion assays, tube-formation assays, multiplex assays of variant effect, and database mining and machine learning models. The selection of the appropriate experimental approach largely depends on the molecular mechanism of the gene under investigation and the predicted functional effect of the VUS. However, before making final decisions regarding the pathogenicity of VUSs, it is essential to assess the functional evidence and clinical outcomes under current variant interpretation guidelines. The inclusion of a functional genomics infrastructure within the PSGT framework will significantly advance the reclassification of VUSs and enhance the precision medicine pipeline for patients with breast carcinomas in South Africa.
Keywords: Breast cancer; Functional genomics; Pathology-supported genetic testing; Precision medicine; Variants of uncertain significance.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MJK is a non-executive director and shareholder of Gknowmix Pty Ltd., to facilitate genetic research translation into clinical practice. DWO is a consultant for Gknowmix Pty Ltd. The other authors have no conflict interest to declare.
Similar articles
-
Application of advanced molecular technology in the diagnosis and management of genetic disorders in South Africa.S Afr Med J. 2016 May 25;106(6 Suppl 1):S114-8. doi: 10.7196/SAMJ.2016.v106i6.11012. S Afr Med J. 2016. PMID: 27245544
-
Genomic medicine and risk prediction across the disease spectrum.Crit Rev Clin Lab Sci. 2015;52(3):120-37. doi: 10.3109/10408363.2014.997930. Epub 2015 Jan 19. Crit Rev Clin Lab Sci. 2015. PMID: 25597499 Review.
-
Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics.BMC Med Genomics. 2022 Mar 26;15(1):70. doi: 10.1186/s12920-022-01214-y. BMC Med Genomics. 2022. PMID: 35346197 Free PMC article.
-
Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.Clin Cancer Res. 2022 Sep 1;28(17):3742-3751. doi: 10.1158/1078-0432.CCR-22-0203. Clin Cancer Res. 2022. PMID: 35736817 Free PMC article.
-
High-Throughput Assays to Assess the Functional Impact of Genetic Variants: A Road Towards Genomic-Driven Medicine.Clin Transl Sci. 2017 Mar;10(2):67-77. doi: 10.1111/cts.12440. Epub 2017 Feb 18. Clin Transl Sci. 2017. PMID: 28213901 Free PMC article. Review. No abstract available.
Cited by
-
Incorporating familial risk, lifestyle factors, and pharmacogenomic insights into personalized noncommunicable disease (NCD) reports for healthcare funder beneficiaries participating in the Open Genome Project.Ann Hum Genet. 2025 Jul;89(4):208-227. doi: 10.1111/ahg.12582. Epub 2024 Oct 29. Ann Hum Genet. 2025. PMID: 39470271 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical